NNNN vs DBVT vs AGEN vs NVAX vs REGN

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Novavax, Inc. (NVAX) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 4. 0x versus Anbio Biotechnology Class A Ordinary Shares at 461. 4x. On forward P/E, Agenus Inc. is actually cheaper at 2. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Anbio Biotechnology Class A Ordinary Shares (NNNN) delivered a total return of +347.

8%, compared to -93. 7% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: NNNN returned +347. 8% versus AGEN's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Anbio Biotechnology Class A Ordinary Shares (NNNN) is the lower-risk stock at 0.

46β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 462% more volatile than NNNN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Anbio Biotechnology Class A Ordinary Shares grew EPS 366. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, NNNN leads at 22. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -18. 0% for AGEN. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 2. 9x forward P/E versus 15. 5x for Regeneron Pharmaceuticals, Inc. — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 134. 8% to $46. 33.

In this comparison, REGN (0.

5% yield) pays a dividend. NNNN, DBVT, AGEN, NVAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Anbio Biotechnology Class A Ordinary Shares (NNNN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

46), +347. 8% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NNNN: +347. 8%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NNNN is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; AGEN is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.